ARTICLE | Company News
Bavarian Nordic will conduct a Phase II bladder cancer trial combining its CV301 with Roche’s Tecentriq atezolizumab. Both companies will share data from the trial, which is slated to begin around YE17.
The Phase II trial will treat patients with locally advanced or metastatic urothelial carcinoma who progressed during or after platinum-containing chemotherapy or who progressed within 12 months of neoadjuvant or adjuvant platinum chemotherapy. Tecentriq has accelerated approval in the U.S. for the indication. The human mAb against PD-L1 is also approved to treat metastatic non-small cell lung cancer (NSCLC)...